Actinogen Medical Limited

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Actinogen Medical (ASX:ACW) is biotechnology company developing novel therapies for neurological and other diseases associated with the ill effects of chronically elevated cortisol. The company's lead drug, Xanamem, works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to detrimental changes in the brain, affecting memory, cognitive function and behaviour and neuropsychological symptoms.
The Company plans to initiate Phase II studies of Xanamem in various disease areas in 2021, including MCI due to Alzheimer’s disease, and Fragile X syndrome.
Ticker:
ACW
Exchange:
Australian Stock Exchange
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Xanamem
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
One
Speaker
photo
Chief Executive Officer
Actinogen Medical